Eyenuk which is a leading developer of advanced artificial intelligence enabled clinically supported solutions to identify diseases via retinal image analysis declared that it has received a Medical Device License from Health Canada for its AI-enabled cloud-based diabetic retinopathy (DR) automated screening software system, EyeArt (v2.1.0).
The Canadian Medical Device License allows Eyenuk to begin commercializing EyeArt™ and begin sales throughout Canada. Building upon Eyenuk’s successful launch in Europe, this Health Canada license supports Eyenuk’s objective to expand the global availability of EyeArt to more clinicians seeking tools for improved screening of diabetic retinopathy in their patients at the point of care.
EyeArt incorporates the software indicated for use by health care professionals including nurses or technicians, and does not require expert human grading or an over-read from an eye care specialist. EyeArt™ screening software is designed to return results within 60 seconds and work with most fundus cameras that provide quality images. With EyeArt Eyenuk aims to make available a cost-effective approach to diabetic retinopathy screening that can be deployed at mass scales in the primary health care setting.
Kaushal Solanki, Founder and CEO of Eyenuk said “ Access to eye screening is limited and expensive for many patients and as a result diabetic retinopathy is the leading cause of preventable blindness, especially impacting working-age adults across the world. We are proud to expand EyeArt™ to additional countries in an effort to make diabetic eye screening more accessible, more efficient, and less expensive, thereby reducing the number of patients losing vision as a complication of diabetes.”